E This research examines the evolution of Corporate Social Responsibility from a compliance-driven obligation into a strategic framework for global development within the Indian pharmaceutical industry. While statutory mandates under the Companies Act, 2013, historically focused corporate metrics on expenditure and basic compliance, this study addresses a critical research gap by mapping actual CSR initiatives to the United Nations Sustainable Development Goals (SDGs).  Adopting a descriptive research design, the study utilizes content and frequency analysis to evaluate the financial year 2024-2025 disclosures of ten leading Indian pharmaceutical companies.  The empirical findings reveal a highly skewed distribution of SDG commitments.  Driven by an inherent industry alignment, SDG 3 (Good Health and Well-being) achieved maximum saturation, with all ten surveyed firms prioritising health care infrastructure, medicine access and community wellness.  Similarly, SDG 4 (Quality Education) emerged as a secondary pillar, reflecting robust corporate investment in human capital through scholarships and academic infrastructure. Conversely, the data uncovers a significant structural imbalance: critical goals such as SDG 5 (Gender Equality) and SDG 13 (Climate Action) received negligible corporate attention, indicating that environmental sustainability and structural equity remain peripheral to sectoral CSR strategies.  The study concludes that while Indian pharmaceutical leaders successfully leverage their core competencies for health and education, their sustainability frameworks remain siloed.  To transcend basic compliance and foster a holistic developmental impact, the sector must diversify its portfolios toward these underrepresented, systemic global challenges